---
title: "Vabysmo (faricimab-svoa), all indications: Pharmacology questions"
description: "Pharmacology questions on Vabysmo (faricimab-svoa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Vabysmo work (mechanism of action)? How long does Vabysmo suppress Ang-2 and VEGF-A after a dose? How is Vabysmo metabolized? How long does Vabysmo stay in your system (half-life)? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa), all indications: Pharmacology questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)  
Indication pages: [Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)

## Mechanism

<a id="vabysmo-mechanism"></a>

### How does Vabysmo work (mechanism of action)?

> “Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by 
> binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell 
> proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is 
> thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. 
> Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of 
> Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet 
> to be established.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

<a id="vabysmo-ang2-vegf-suppression"></a>

### How long does Vabysmo suppress Ang-2 and VEGF-A after a dose?

> “VABYSMO suppressed Ang-2 and VEGF-A for up to 16 weeks after initial dosing<sup>1,9†</sup>”

Source: [VABYSMO: How VABYSMO Works in nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/how-it-works.html#:~:text=VABYSMO%20suppressed%20Ang%2D2%20and%20VEGF%2DA%20for%20up%20to%2016%20weeks%20after%20initial)

> “Pharmacodynamic analysis in aqueous humor of patients with nAMD or DME in Phase 2 and 3 trials: Ang-2 and VEGF-A levels did not return to baseline 16 weeks after a dose.<sup>9</sup>”

Source: [VABYSMO: How VABYSMO Works in nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/how-it-works.html#:~:text=Pharmacodynamic%20analysis%20in%20aqueous%20humor,baseline%2016%20weeks%20after%20a)

> “The contribution of Ang-2 inhibition to the clinical response for nAMD, DME, and RVO has yet to be established.<sup>1</sup>”

Source: [VABYSMO: How VABYSMO Works in nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/how-it-works.html#:~:text=The%20contribution%20of%20Ang%2D2%20inhibition,RVO%20has%20yet%20to%20be)

## Pharmacokinetics

<a id="vabysmo-metabolism"></a>

### How is Vabysmo metabolized?

> “Metabolism and elimination of faricimab has not been fully characterized. Faricimab is expected 
> to be catabolized in lysosomes to small peptides and amino acids, which may be excreted 
> renally, in a similar manner to the elimination of endogenous IgG.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

<a id="vabysmo-half-life"></a>

### How long does Vabysmo stay in your system (half-life)?

> “The estimated mean apparent 
> systemic half-life of faricimab is approximately 7.5 days.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

> “Maximum faricimab plasma concentrations (Cmax) are estimated to occur approximately 2 days 
> post-dose.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

<a id="vabysmo-accumulation"></a>

### Does Vabysmo build up in the body with repeated injections?

> “After repeated intravitreal administrations, mean plasma free faricimab trough 
> concentrations are predicted to be 0.002-0.003 mcg/mL for every 8 weeks (Q8W) dosing and 
> 0.021-0.029 mcg/mL for every 4 weeks (Q4W) dosing. Although not directly measured in the 
> vitreous, no accumulation of faricimab is expected in the vitreous and no accumulation has been 
> observed in plasma when faricimab has been administered as repeat doses in the vitreous.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

## Components

<a id="vabysmo-inactive-ingredients"></a>

### What are the inactive ingredients in Vabysmo?

> “VABYSMO (faricimab-svoa) injection is a sterile, clear to opalescent, colorless to 
> brownish-yellow solution in a single-dose prefilled glass syringe or glass vial for intravitreal 
> administration. Each single-dose prefilled syringe or single-dose vial is designed to deliver 0.05 
> mL (50 microliters) of solution containing 6 mg faricimab-svoa, L-histidine (155 mcg), L-
> methionine (52.2 mcg), polysorbate 20 (20 mcg), sodium chloride (73.1 mcg), D-sucrose (2.74 
> mg) and Water for Injection, adjusted to pH 5.5 with acetic acid. The product does not contain an 
> anti-microbial preservative.”

Source: [VABYSMO: Prescribing information, page 14, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=14)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): All indications](https://www.evicenter.com/medical-information/vabysmo)
- [Indication](https://www.evicenter.com/medical-information/vabysmo/indication)
- [Safety](https://www.evicenter.com/medical-information/vabysmo/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vabysmo/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vabysmo/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vabysmo/access-and-coverage)
